T cell proliferation assays

Mixed lymphocyte reaction assays

T cell activation by APCs, modelled in high throughput.

Horizon’s Mixed Lymphocyte Reaction (MLR) Assay allows for the rapid identification of agents that modulate APC-mediated T cell activation. Assay your biologics or small molecules as single agents or in combination in high throughput.

Leveraging our extensive experience in combination high throughput screening, our method will provide analysis and interpretation of the effects of your biologics or small molecules on multiple endpoints from multiple allogeneic donors.

How does our MLR assay work?

MLR How

How can Horizon’s MLR assay move your therapeutic candidate forward?

  • 384-well assay: Automated, robust and highly reproducible high throughput assay for large scale screening
  • Single agents or combinations: Flexible assay design that can be readily customized to fit your project
  • Multiple allogeneic donors: Highly enriched human primary T cells and monocyte derived dendritic cells from multiple donors to address donor-to-donor variability
  • Multiple endpoints: Surface markers, cytokines, and cell proliferation—clearly understand the immuno-modulatory profile of your candidates
  • 10+ years of combination screening experience: Expert data analysis and interpretation using our proprietary Chalice Analyzer software

Mixed Lymphocyte Fig1

Figure 1. Robust MLR response in five different
human allogeneic donors as measured by IFNγ secretion (HTRF)

Mixed Lymphocyte Fig2

Figure 2. Anti-PD-1 antibody nivolumab
promotes IFNγ secretion (HTRF) in an allogeneic MLR assay

Request more information

T cell activation assays

Rapidly identify agents that modulate T cells, as single agents or in combination, in high throughput leveraging Horizon’s extensive experience in combination high throughput screening. We’ll provide analysis and interpretation of the effects of your biologics or small molecules on multiple endpoints from multiple donors.

Our T-cell activation assay process

  • Horizon isolates T-cells from multiple donors
  • T-cells are cultured with CD3 and CD28
  • Small molecules or biologics are added as single agents or in combination
  • Endpoints measured: cell suface markers, cytokine release and cell proliferation

High throughput assays: Moving your therapeutic candidate forward

  • 384-well assay: Automated, robust and highly reproducible high throughput assay for large scale screening
  • Single agents or combinations: Flexible assay design that can be readily customized to fit your project
  • Multiple T cell donors: Highly enriched human primary T cells from multiple donors to address donor-to-donor variability
  • Multiple endpoints: Surface markers, cytokine release and cell proliferation—clearly understand the immuno-modulatory profile of your candidates
  • 10+ years of combination screening experience: Expert data analysis and interpretation using our proprietary Chalice Analyzer software

T-Cell Diagram 1

Figure 1. Synergistic activation of T cells by α-CD3/CD28 antibodies as measured by IL-2 secretion. Values in left matrix represent % activation of T cells. Values in right matrix
represent synergistic activity above single agent as indicated by Loewe Additivity Model.

Tcell Activation Fig2

Figure 2. Anti-PD-1 antibody nivolumab promotes T cell proliferation by anti-CD3/CD28 in the presence of sPD-L1.

Request more information